Optimization of an Aqueous Tablet-Coating Process Containing Carboxymethylated Cassia fistula Gum
Abstract The present investigation was aimed at developing and optimizing a simple aqueous tablet-coating formulation and its process. 5-Fluorouracil (5-FU) was used to ascertain the relative lipophilic/hydrophilic behavior of the coating system. Optimization was performed by evaluating the adhesive force strength and cohesive force strength of the tablet coat using a texture analyzer. The in vitro release of 5-FU was found to decrease with an increase in (tablet surface-coat) adhesive force strength. The (tablet–tablet) cohesive force strength was reduced by the addition of magnesium silicate to the coating solution. The addition of magnesium silicate (0.2% w/v) to the carboxymethyl Cassia fistula gum–chitosan (CCG–CH) coating surface significantly inhibited the release of 5-FU possibly due to an increase in the hydrophobic character of the coated tablet surface. This was possible by coating cohesive force strength reduction coating compositions (CCG–CH (70:30) and 0.3% magnesium silicate). Further, the FTIR-ATR and DSC analyses suggested the pivotal role of magnesium silicate in modifying the release of 5-FU from CCG–CH-coated tablets due to hydrogen bonding of its Si–O–Si or Mg–O groups with –OH moieties of CCG–CH..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
AAPS PharmSciTech - 13(2012), 2 vom: 24. Feb., Seite 431-440 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rai, Parshu Ram [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© American Association of Pharmaceutical Scientists 2012 |
|---|
| doi: |
10.1208/s12249-012-9763-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR024888532 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR024888532 | ||
| 003 | DE-627 | ||
| 005 | 20230519082713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12249-012-9763-x |2 doi | |
| 035 | |a (DE-627)SPR024888532 | ||
| 035 | |a (SPR)s12249-012-9763-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rai, Parshu Ram |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimization of an Aqueous Tablet-Coating Process Containing Carboxymethylated Cassia fistula Gum |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © American Association of Pharmaceutical Scientists 2012 | ||
| 520 | |a Abstract The present investigation was aimed at developing and optimizing a simple aqueous tablet-coating formulation and its process. 5-Fluorouracil (5-FU) was used to ascertain the relative lipophilic/hydrophilic behavior of the coating system. Optimization was performed by evaluating the adhesive force strength and cohesive force strength of the tablet coat using a texture analyzer. The in vitro release of 5-FU was found to decrease with an increase in (tablet surface-coat) adhesive force strength. The (tablet–tablet) cohesive force strength was reduced by the addition of magnesium silicate to the coating solution. The addition of magnesium silicate (0.2% w/v) to the carboxymethyl Cassia fistula gum–chitosan (CCG–CH) coating surface significantly inhibited the release of 5-FU possibly due to an increase in the hydrophobic character of the coated tablet surface. This was possible by coating cohesive force strength reduction coating compositions (CCG–CH (70:30) and 0.3% magnesium silicate). Further, the FTIR-ATR and DSC analyses suggested the pivotal role of magnesium silicate in modifying the release of 5-FU from CCG–CH-coated tablets due to hydrogen bonding of its Si–O–Si or Mg–O groups with –OH moieties of CCG–CH. | ||
| 700 | 1 | |a Tiwary, Ashok Kumar |4 aut | |
| 700 | 1 | |a Rana, Vikas |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AAPS PharmSciTech |d New York, NY : Springer, 2000 |g 13(2012), 2 vom: 24. Feb., Seite 431-440 |w (DE-627)SPR02478785X |w (DE-600)2052070-0 |x 1530-9932 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2012 |g number:2 |g day:24 |g month:02 |g pages:431-440 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1208/s12249-012-9763-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2012 |e 2 |b 24 |c 02 |h 431-440 | ||